Mabpharm Limited (HKG:2181)
Hong Kong
· Delayed Price · Currency is HKD 0.430
+0.020 (4.88%)
At close: Mar 10, 2026
Mabpharm Revenue
Mabpharm had revenue of 274.18M CNY in the half year ending June 30, 2025, with 522.86% growth. This brings the company's revenue in the last twelve months to 423.93M, up 179.59% year-over-year. In the year 2024, Mabpharm had annual revenue of 258.23M with 196.27% growth.
Revenue (ttm)
423.93M CNY
Revenue Growth
+179.59%
P/S Ratio
3.64
Revenue / Employee
1.11M CNY
Employees
383
Market Cap
1.69B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cutia Therapeutics | 274.31M |
| Zhaoke Ophthalmology | 38.74M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 134.60M |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.43B |
| Kintor Pharmaceutical | 12.04M |
| CANbridge Pharmaceuticals | 68.55M |
| Beijing Biostar Pharmaceuticals | 58.66M |
| Frontage Holdings | 1.99B |